Chromologics: Gerit Tolborg shares how to get funded in 2026

Investment Climate Podcast: Fundraising Playbooks From Food Tech CEOs and VCs

In this podcast series, Alex Shandrovsky interviews investors about benchmarks for funding Alt Proteins in 2025 and uncovers the investment playbooks of successful Climate Tech CEOs and Leading VCs.

Podcast Host Alex Shandrovksy is a strategic advisor to numerous global food tech accelerators and companies, including alternative proteins and cellular agriculture leaders. His focus is on investor relations and post-raise scale for agrifood tech companies. This podcast is syndicated through our media partners, Foodtech Weekly and Vegconomist.

Episode 60: Chromologics: Gerit Tolborg shares how to get funded in 2026

In this episode, I sit down with Gerit Tolborg, co-founder & CEO of Chromologics, to unpack how you turn a PhD discovery—a fungus that naturally makes a brilliant red pigment—into a venture-backed ingredient company on the brink of FDA/EFSA submission. We talk about why Chromologics chose to raise a fully insider round instead of going back to the market, how weird and “all-or-nothing” the regulatory world is for food colorants, and why red is both the biggest commercial opportunity and the hardest technical problem. Gerit walks through the real economics of natural colors (performance vs price vs supply chain risk), why their non-GMO fermentation process is a quiet superpower with regulators and consumers, and how she thinks about scaling via CMOs first instead of betting the company on a big CapEx plant. If you care about where the next generation of clean-label ingredients will actually come from—and what investors really underwrite in these plays—this conversation goes deep.

Key Facts Chromologics:

Goal: Develop fermentation-derived, natural food colors to replace unstable, supply-constrained, and animal-derived reds
Recently raised €7 million from Novo Holdings, EIFO, Döhler Ventures, Collateral Good, and The Synergetic Group, bringing its total funding to nearly €20 million.

Alex’s Top Findings:

When Your Biggest Risk Is Invisible: Fundraising Around Regulation. Chromologics deliberately raised a €7M internal round from existing shareholders (Novo Holdings, EIFO) instead of going to market. They’re at a sensitive regulatory inflection point where colors are “all or nothing” until dossier submission—something incumbents who’ve watched the journey can underwrite more easily than new VCs. This path lets Gerit focus on building and de-risking instead of burning months on data rooms and external DD for a hard-to-price stage. ” So from an outside investor, the risk-reward balance is maybe not so easy to grasp as from someone who's actually been following our journey all the way and really seen us step-wise, maturing and de-risking the regulatory process along the way. So if there's enough capital around the table that we actually would need to bring the company from where we are today, it would have been a really big next value inflection point. Why waste valuable time and maybe risk unfavorable valuation if we can just manage on our own?”
CDMOs Now, Strategic Exit Later. In today’s market, Gerit sees little sense in raising huge CapEx for a plant before proving commercial pull. Chromologics has already lined up a CDMO and designed its process to work at standard 100 m³ fermentation scale, where the economics make sense. Long term, she expects the real upside to be in a strategic exit: a large ingredient or food company plugging Chromologics’ IP and regulatory dossiers into its own, cheaper capacity. “ I think there's no investor right now that is willing to invest a hundred million euros into a CapEx project before I ev